Background: Excessive daytime sleepiness and cataplexy are among the symptoms of narcolepsy,
a sleep disorder caused by the loss of hypocretin/orexin (HCRT/OX) neurons placed into the
Hypothalamus (LH). Several treatments for managing narcolepsy include diverse drugs to induce
alertness, such as antidepressants, amphetamine, or modafinil, etc. Recent evidence has shown that
cannabidiol (CBD), a non-psychotropic derived from Cannabis sativa, shows positive therapeutic effects
in neurodegenerative disorders, including Parkinson´s disease. Furthermore, CBD provokes
alertness and enhances wake-related neurochemicals in laboratory animals. Thus, it is plausible to hypothesize
that excessive somnolence observed in narcolepsy might be blocked by CBD.
Objective: Here, we determined whether the systemic injection of CBD (5mg/kg, i.p.) would block the
excessive sleepiness in a narcoleptic model.
Methods: To test this idea, the neurotoxin hypocretin-2-saporin (HCRT2/SAP) was bilaterally injected
into the LH of rats to eliminate HCRT leading to the establishment of narcoleptic-like behavior. Since
excessive somnolence in HCRT2/SAP lesioned rats has been observed during the lights-off period,
CBD was administered at the beginning of the dark phase.
Results: Hourly analysis of sleep data showed that CBD blocked the sleepiness during the lights-off
period across 7h post-injection in lesioned rats.
Conclusion: Taking together, these preliminary findings suggest that CBD might prevent sleepiness in